反应详情

The product is prepared according to the procedure described in Stage 2 of Example 2, using 700 mg of N-(5-fluoro-2-hydroxyphenyl)-2-[4-(morpholin-4-yl)-6-oxo-1,6-dihydropyrimidin-2-yl]acetamide and 292 mg of 4-methylbenzenesulphonic acid hydrate, and replacing the toluene with xylene. After purification by silica gel column chromatography, elution being carried out with a mixture of CH2Cl2/MeOH: 98/02, then CH2Cl2/MeOH: 95/05, followed by recrystallization from methanol, 188 mg of 2-[(5-fluoro-1,3-benzoxazol-2-yl)methyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one are obtained in the form of a brown solid, the characteristics of which are the following:

1. customThe product is prepared
2. customAfter purification
3. washby silica gel column chromatography, elution
4. additionbeing carried out with a mixture of CH2Cl2/MeOH
5. custom98/02, then CH2Cl2/MeOH: 95/05, followed by recrystallization from methanol, 188 mg of 2-[(5-fluoro-1,3-benzoxazol-2-yl)methyl]-6-(morpholin-4-yl)pyrimidin-4(3H)-one
6. customare obtained in the form of a brown solid